组蛋白去乙酰化酶抑制剂与癌症表观遗传（及更多方面）治疗的前景。

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

作者信息

Minucci Saverio, Pelicci Pier Giuseppe

机构信息

Department of Experimental Oncology, European Institute of Oncology, Via Ripamanti 435, 20141, Milan, Italy.

出版信息

Nat Rev Cancer. 2006 Jan;6(1):38-51. doi: 10.1038/nrc1779.

DOI:10.1038/nrc1779

PMID:16397526

Abstract

Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.

摘要

组蛋白去乙酰化酶（HDACs）被认为是癌症治疗药物开发中最有前景的靶点之一，第一代组蛋白去乙酰化酶抑制剂（HDACi）目前正在进行I/II期临床试验。人们已经对HDACs在肿瘤发生中的作用以及HDACi的作用有了广泛的了解。然而，几个基本方面尚未完全理解。在我们目前对HDACi在体外和体内作用的理解背景下研究这些方面，将进一步改进优化临床方案的设计。